Clinical trials: Distant Metastasis
Advanced Prostate Carcinoma
The Wolverhampton Assessment Tool, a Tool for Patient-reported Wellbeing in the Context of Prostate Cancer
This is a study of the Wolverhampton Assessment Tool (WATapp), a five-item questionnaire for patients with advanced or metastatic prostate cancer to say how they feel normally in terms of pain, urinary frequency, eating, and…
- Trial name
- WATapp (NCT04851639)
- Testing
- Wolverhampton Assessment Tool
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Wolverhampton
Pancreatic Cancer Resectable
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head.
- Trial name
- ASAP (NCT05637567)
- Testing
- Acetylsalicylic acid
- Volunteers
- 170 people
- Sponsor
- German Cancer Research Center
Stomach Neoplasms, Benign
Identification of Therapeutic Targets in Metastatic Gastric Cancer
This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis.
- Trial name
- NCT07551440
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for…
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3
- Trial name
- NCT03518320
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Taris Biomedical LLC
Stroke
Iron Chelation in the Prevention of Secondary Degeneration After Stroke
Stroke is a major cause of disability over the world. While acute therapies have made huge progresses, the number of survivors leaving with clinical consequences of stroke is increasing.
- Trial name
- CHEL-IC (NCT05111821)
- Testing
- Magnetic Resonance Imaging (MRI), Deferiprone treatment
- Where
- 2 sites in France
- Volunteers
- 11 people
- Sponsor
- University Hospital, Bordeaux
Melanoma
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
This is a single arm open label, multicenter, non randomized, access study of trametinib for subjects with histologically confirmed cutaneous melanoma with a BRAF V600E/K positive mutation that is either advanced unresectable…
- Trial name
- NCT02416232
- Testing
- Trametinib, Dabrafenib
- Where
- 46 sites in France
- Sponsor
- GlaxoSmithKline
Gastroesophageal Cancer (GC)
First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial
The aim of the study is to evaluate the efficacy of radiotherapy on the primary site of gastroesophageal cancer and extracranial stereotactic radiotherapy on metastases before the use of standard systemic therapy, in cases of…
- Trial name
- SOCRATE (NCT06922279)
- Testing
- Radiation Therapy + standard sistemic therapy (chemoteraphy), Standard systemic therapy (chemotherapy)
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer
Choline-PET for Evaluating the Incidence of Nodal Metastases Among Newly Diagnosed Patients of Prostate Cancer
Nodal involvement among patients with prostate cancer is known to be a poor prognostic factor. Traditionally, the presence or absence of nodal disease in patients with prostate cancer is ascertained with the use of anatomical…
- Trial name
- ChoPEN (NCT01769950)
- Testing
- Choline-PET
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Bangalore Institute of Oncology
Metastatic Melanoma
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy…
- Trial name
- NCT00226473
- Testing
- Cisplatin, Vindesine, Dacarbazine (drugs)
- Where
- 13 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer
This is a multicenter, observational validation study designed to evaluate the prognostic performance of the PORTENT algorithm in patients with early-stage breast cancer.
- Trial name
- PORTENT (NCT07372261)
- Testing
- Validation of Prognostic tool
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Hepatocellular Carcinoma
Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization
This project will include at least 40 patients with hepatocellular carcinoma (HCC) who will receive transcatheter arterial chemoembolization (TACE) as a sole method for the management.
- Trial name
- NCT00834028
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Breast Cancer Female
Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients
A study that evaluates the benefits of a personalized remote exercise and physical activity coaching compared with the standard supportive approach in terms of health-related quality of life at 12 months in breast cancer…
- Trial name
- eMOUVOIR (NCT04536584)
- Testing
- Personalized Coaching (Arm A), Standard supportive approach (Arm B)
- Where
- 22 sites in France
- Volunteers
- 824 people
- Sponsor
- Centre Oscar Lambret
Castration-Resistant Prostate Cancer
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.
- Trial name
- PREDICT (NCT01981109)
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Dendreon
Recurrent Head and Neck Squamous Cell Carcinoma
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases.
- Trial name
- ECLIPSE (NCT06699212)
- Testing
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 412 people
- Sponsor
- Rakuten Medical, Inc.
Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent
EpCAM CAR-T for Treatment of Advanced Solid Tumors
This study is for patients that have nasopharyngeal carcinoma, breast cancer, gastric cancer and other solid tumors. As epithelial cell adhesion molecule (EpCAM) is a well characterized molecule that is closely with poor…
- Conditions
- Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent, Gastric Cancer With Metastasis
- Trial name
- NCT02915445
- Testing
- EpCAM CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Lung Cancer, Small Cell, Pancreatic Cancer
Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Accurate evaluation of activity status is an important part of the assessment of people with cancer. Clinician assessments currently used are valuable but have limitations; in particular, assessment only occurs when the patient…
- Conditions
- Lung Cancer, Small Cell, Pancreatic Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- WATTOX (NCT04440800)
- Testing
- Wearable activity tracker - FitBit
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Rare Cancers, Cholangiocarcinoma
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
- Conditions
- Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
- Trial name
- TRACK (NCT04504604)
- Testing
- FoundationOne CDx and FoundationOne Liquid CDx
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- TargetCancer Foundation
Cervical Cancer Squamous Cell, Human Papilloma Virus Infection
Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas
This study evaluates the women cervical samples through molecular tests in order to: 1. Deploy the test careHPV (hybrid capture test) in mobile unities of the Barretos Cancer Hospital to evaluate their performance;
- Conditions
- Cervical Cancer Squamous Cell, Human Papilloma Virus Infection, Human Papilloma Virus-Related Carcinoma, Prevention
- Trial name
- careHPV (NCT01539668)
- Where
- 2 sites in Brazil
- Volunteers
- 5,079 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital
Nasopharyngeal Carcinoma
Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more.
- Trial name
- NCT03290820
- Testing
- Radiotherapy, Concurrent chemotherapy, Aspirin
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Sun Yat-sen University
Local Advanced High Risk Nasopharyngeal Carcinoma
Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients
This is a randomized,controlled,prospective phase III clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant…
- Trial name
- NCT02973386
- Testing
- IMRT combine with cisplatin concurrent chemotherapy, IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Sun Yat-sen University